title: Bendamustine salvage therapy for T cell neoplasms.
abstract: Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.
authors.affiliation: Clinica Ematologica, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, p.le S. Maria Misericordia 15, 33100, Udine, Italy. zaja.francesco@aoud.sanita.fvg.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Luca
authors.initials: L
authors.lastname: Baldini
authors.forename: Andrés J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Stefano
authors.initials: S
authors.lastname: Luminari
authors.forename: Alberto
authors.initials: A
authors.lastname: Grossi
authors.forename: Flavia
authors.initials: F
authors.lastname: Salvi
authors.forename: Renato
authors.initials: R
authors.lastname: Zambello
authors.forename: Maria
authors.initials: M
authors.lastname: Goldaniga
authors.forename: Stefano
authors.initials: S
authors.lastname: Volpetti
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride